Exicure Shares Are Trading Higher After the Company Announced It Entered Into a Patent License Agreement With Bluejay Therapeutics to Develop Cavrotolimod for the Potential Treatment for Hepatitis
Exicure宣佈與Bluejay Therapeutics簽訂專利許可協議,開發用於潛在肝炎治療的卡夫羅託莫德後,該公司股價走高